|
10/04/2025
|
07:00
|
MaxCyte to Report Q1 2025 Results on May 7, 2025
|
RNS
|
|
08/04/2025
|
15:35
|
Holding(s) in Company
|
RNS
|
|
01/04/2025
|
17:57
|
Total Voting Rights
|
RNS
|
|
26/03/2025
|
10:14
|
Correction: Vesting of RSUs and PDMR Dealing
|
RNS
|
|
26/03/2025
|
07:00
|
Vesting of RSUs and PDMR Dealing
|
RNS
|
|
25/03/2025
|
10:30
|
Holding(s) in Company
|
RNS
|
|
25/03/2025
|
10:28
|
Holding(s) in Company
|
RNS
|
|
25/03/2025
|
10:26
|
Holding(s) in Company
|
RNS
|
|
25/03/2025
|
10:22
|
Holding(s) in Company
|
RNS
|
|
24/03/2025
|
09:06
|
Grant of Options, RSUs and PSUs and PDMR Dealing
|
RNS
|
|
19/03/2025
|
14:07
|
Holding(s) in Company
|
RNS
|
|
12/03/2025
|
07:01
|
Filing of Form 10-K for FY ended December 31, 2024
|
RNS
|
|
12/03/2025
|
07:00
|
Q4 & FY 2024 Financial Results
|
RNS
|
|
04/03/2025
|
15:38
|
Total Voting Rights
|
RNS
|
|
19/02/2025
|
15:23
|
Holding(s) in Company
|
RNS
|
|
14/02/2025
|
17:05
|
Holding(s) in Company
|
RNS
|
|
13/02/2025
|
16:12
|
Holding(s) in Company
|
RNS
|
|
13/02/2025
|
14:52
|
Holding(s) in Company
|
RNS
|
|
12/02/2025
|
07:00
|
Strategic Platform License with TG Therapeutics
|
RNS
|
|
07/02/2025
|
07:00
|
Notice of Results
|
RNS
|
|
04/02/2025
|
07:00
|
Total Voting Rights
|
RNS
|
|
31/01/2025
|
15:18
|
Exercise of options and PDMR dealing
|
RNS
|
|
30/01/2025
|
07:00
|
MaxCyte® Acquires SeQure Dx
|
RNS
|
|
29/01/2025
|
15:05
|
Holding(s) in Company
|
RNS
|
|
22/01/2025
|
14:25
|
Holding(s) in Company
|
RNS
|
|
21/01/2025
|
09:13
|
Holding(s) in Company
|
RNS
|
|
17/01/2025
|
13:15
|
Holding(s) in Company
|
RNS
|
|
15/01/2025
|
16:00
|
Holding(s) in Company
|
RNS
|
|
13/01/2025
|
08:05
|
Preliminary Fourth Quarter and Full Year Results
|
RNS
|
|
02/01/2025
|
17:53
|
Total Voting Rights
|
RNS
|
|
31/12/2024
|
07:00
|
Exercise of options and PDMR dealing
|
RNS
|
|
23/12/2024
|
07:00
|
MaxCyte Announces Retirement of Board Member
|
RNS
|
|
19/12/2024
|
16:26
|
Holding(s) in Company
|
RNS
|
|
18/12/2024
|
15:31
|
Holding(s) in Company
|
RNS
|
|
10/12/2024
|
17:16
|
Holding(s) in Company
|
RNS
|
|
10/12/2024
|
17:12
|
Holding(s) in Company
|
RNS
|
|
09/12/2024
|
07:00
|
MaxCyte Streamlines Operations and Raises Guidance
|
RNS
|
|
02/12/2024
|
17:09
|
Total Voting Rights and Block Listing Return
|
RNS
|
|
28/11/2024
|
15:05
|
Holding(s) in Company
|
RNS
|
|
28/11/2024
|
15:05
|
Holding(s) in Company
|
RNS
|
|
19/11/2024
|
09:49
|
Holding(s) in Company
|
RNS
|
|
07/11/2024
|
07:00
|
Third Quarter 2024 Financial Results
|
RNS
|
|
07/11/2024
|
07:00
|
Filing of 10Q form
|
RNS
|
|
06/11/2024
|
13:43
|
Exercise of options and PDMR dealing
|
RNS
|
|
04/11/2024
|
13:23
|
Total Voting Rights
|
RNS
|
|
31/10/2024
|
07:00
|
Exercise of options and PDMR dealing
|
RNS
|
|
18/10/2024
|
09:24
|
Grant of Options and Restricted Stock Units
|
RNS
|
|
15/10/2024
|
13:05
|
MaxCyte Appoints Cynthia Collins to Board
|
RNS
|
|
11/10/2024
|
13:00
|
Notice of Results
|
RNS
|
|
10/10/2024
|
13:05
|
MaxCyte Appoints Ali Soleymannezhad as CCO
|
RNS
|